Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer.

Taken together, our data indicate that GP-2250 exerts profound effects on tumor metabolism and, in combination with PARP inhibitors or bevacizumab, showed promising anti-tumor efficacy. These findings could have implications for the clinical development of GP-2250.